Prof. Jian Zhang 张剑
Chief Physician, Professor
Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment of breast cancer and early-phase clinical trials of new anti-cancer drugs for all tumor types.
Dr. Zhang is Chief Physician and Professor at Fudan University Shanghai Cancer Center, leading its Phase I Clinical Research Center. Trained at START (USA) and Harvard University, Dr. Zhang specializes in breast cancer guidelines and early-phase drug development. Research includes the GP regimen for triple-negative breast cancer and HER2 heterogeneity studies presented at ASCO and ESMO.
Professional roles
- Chair, Tumor Drug Clinical Research Professional Committee, China Medical Education Association
- Chair, Tumor Prevention and Clinical Research Management Professional Committee, China Health Care Association for the Elderly
- Chair, Yangtze River Academic Belt Oncology Collaboration Group (YCOG)
- Standing Committee Member, Breast Cancer Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Zhang Jian). Papers usually list the name as Jian Zhang or Zhang J.
Selected publications
211 papers on PubMed matched by name and affiliation; 55 as first or senior author since 2016. Most recent first- or senior-author papers:
- Eur J Cancer, 2026 (senior author): A phase I, first-in-human dose-escalation and triple-negative breast cancer dose-expansion study of a TROP2-ADC F0024 (FDA018). PubMed 42810148
- Lancet Oncol, 2026 (first author): Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial. PubMed 42987884
- J Clin Oncol, 2026 (first author): Trastuzumab Botidotin Versus Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2-Positive Advanced Breast Cancer: A Phase III, Open-Label, Randomized Controlled Trial. PubMed 42727044
- Oncogene, 2026 (senior author): AKAP13 regulates GLI1/ULK1 axis and drive tumor resistance to next-generation HER2-targeted therapies. PubMed 42562949
- J Clin Oncol, 2026 (senior author): Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study). PubMed 41779972
- J Clin Oncol, 2026 (senior author): Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for Chemotherapy‑Induced Nausea/Vomiting in Highly Emetogenic Chemotherapy: Phase III Noninferiority Trial. PubMed 42241642
- Adv Sci (Weinh), 2026 (senior author): Pharmacologic Modulation of ARID3A with Rimegepant Reactivates Type I Interferon Signaling and Sensitizes Triple-Negative Breast Cancer to PD-1 Blockade. PubMed 42230325
- Breast Cancer Res Treat, 2026 (senior author): Exploring the potential of postmastectomy radiotherapy in cN + and ypN0 breast cancer patients following neoadjuvant chemotherapy. PubMed 42118193
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion